New liver safety study for experimental drug MDR-001 begins
NCT ID NCT07550634
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study will give a single dose of MDR-001, a GLP-1 receptor agonist tablet, to 32 people: some with mild or moderate liver impairment and some with healthy livers. Researchers want to see how the drug moves through the body and if it is safe in people with liver issues. The goal is to gather information, not to treat the liver condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MDR-001 (a GLP-1 receptor agonist tablet)
What this could lead to
If successful, this study could help doctors understand how to safely dose MDR-001 in patients with liver problems.
What could go wrong
This is a very early Phase 1 trial with only 32 participants. It is designed to measure drug levels and safety, not to treat liver disease. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT (MILD AND MODERATE, CHILD-PUGH CLASS A AND B) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Hospital of Jilin University
Changchun, Jilin, 130021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••